| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Helmut Friess | Q15453363 |
| P2093 | author name string | Thomas E Adrian | |
| Xianzhong Ding | |||
| Rene Hennig | |||
| P2860 | cites work | Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors | Q24315906 |
| Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells | Q24643373 | ||
| Inflammation and cancer | Q24649640 | ||
| 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue | Q24685466 | ||
| 5-lipoxygenase and FLAP | Q28191619 | ||
| Peroxisome proliferator-activated receptor gamma and cancers | Q28204283 | ||
| Prostaglandins and leukotrienes: advances in eicosanoid biology | Q28208246 | ||
| Cyclooxygenases in cancer: progress and perspective | Q28213081 | ||
| Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer | Q28237322 | ||
| Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists | Q28269915 | ||
| BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation | Q28293407 | ||
| ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions | Q28326980 | ||
| Lipoxygenase inhibition in prostate cancer | Q30303985 | ||
| Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells | Q30304683 | ||
| Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells | Q31463666 | ||
| Lipoxygenase-5 is overexpressed in prostate adenocarcinoma | Q32159450 | ||
| LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. | Q33217483 | ||
| Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells | Q33867987 | ||
| Nonsteroidal anti-inflammatory drugs and cancer prevention | Q33896120 | ||
| Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment | Q34007479 | ||
| 12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation | Q34105289 | ||
| The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells | Q34146427 | ||
| Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. | Q34153961 | ||
| Discovery of leukotrienes and development of antileukotriene agents | Q34293766 | ||
| Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. | Q34425964 | ||
| Many actions of cyclooxygenase-2 in cellular dynamics and in cancer | Q34539982 | ||
| Inflammation and the development of pancreatic cancer | Q34646491 | ||
| Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. | Q44248585 | ||
| Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer | Q44541936 | ||
| Effect of LY293111 in combination with gemcitabine in colonic cancer | Q44917325 | ||
| Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. | Q44920013 | ||
| Effect of a leukotriene B4 receptor antagonist on leukotriene B4-induced neutrophil chemotaxis in cavine dermis | Q46411983 | ||
| Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982 | Q46446668 | ||
| Five-lipoxygenase inhibitors reduce Panc-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid. | Q50523996 | ||
| Arachidonate has protumor-promoting action that is inhibited by linoleate in mouse skin carcinogenesis. | Q53455541 | ||
| A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. | Q54439319 | ||
| Modulation of ligand binding to leukotriene B4 receptors on guinea pig lung membranes by sulfhydryl modifying reagents | Q68486637 | ||
| SC-41930: an inhibitor of leukotriene B4-stimulated human neutrophil functions | Q69365300 | ||
| Estimation of antagonistic activity of ONO-4057 against leukotriene B4 in humans | Q72197682 | ||
| Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells | Q73278172 | ||
| A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions | Q73502409 | ||
| Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer | Q34743008 | ||
| Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. | Q35029444 | ||
| Lipoxygenase inhibitors for the treatment of pancreatic cancer | Q35204970 | ||
| n-3 Fatty Acids: Biochemical Actions in Cancer | Q35219907 | ||
| Dietary fat and breast cancer: a search for mechanisms | Q35533624 | ||
| Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. | Q35574131 | ||
| Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms | Q35596926 | ||
| Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. | Q35676053 | ||
| Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract | Q35683844 | ||
| Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. | Q35686407 | ||
| Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy | Q35793283 | ||
| Modern management of pancreatic carcinoma. | Q35866145 | ||
| Malpractice risks associated with colon cancer and inflammatory bowel disease | Q35872046 | ||
| Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force | Q35879592 | ||
| At the crossroads of inflammation and cancer | Q35888450 | ||
| Molecular findings in Barrett's epithelium | Q35895327 | ||
| Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling | Q35913115 | ||
| Current standards of surgery for pancreatic cancer. | Q35925293 | ||
| Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms | Q35929251 | ||
| The role of inflammation in the pathogenesis of prostate cancer | Q35944498 | ||
| 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth | Q36143603 | ||
| Structure-function relationships in sheep, mouse, and human prostaglandin endoperoxide G/H synthases | Q37859017 | ||
| Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells | Q40148512 | ||
| LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways | Q40384304 | ||
| Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. | Q40449143 | ||
| Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. | Q40459624 | ||
| Aspirin, NSAIDs, and digestive tract cancers | Q40504275 | ||
| Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111. | Q40509177 | ||
| Prostaglandin H synthase and lipoxygenase gene families in the epithelial cell barrier | Q40572571 | ||
| Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2. | Q40577066 | ||
| Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer | Q40719747 | ||
| Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo | Q40763133 | ||
| 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. | Q40771073 | ||
| Dietary fat and breast cancer metastasis by human tumor xenografts | Q41056286 | ||
| The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice | Q41245074 | ||
| The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma | Q41338279 | ||
| Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer | Q41382049 | ||
| NSAID use and decreased risk of gastrointestinal cancers | Q41537355 | ||
| Biosynthesis inhibitors for leukotrienes in bronchial asthma. | Q41575787 | ||
| Effect of different types and amounts of fat on the development of mammary tumors in rodents: a review | Q41599731 | ||
| Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies | Q41658498 | ||
| Lipid-dependent proliferation of pancreatic cancer cell lines | Q41674441 | ||
| Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain | Q41966473 | ||
| Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist | Q42274359 | ||
| Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist | Q42279726 | ||
| 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions | Q42812216 | ||
| 7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8- propyl-2H-1-benzopyran-2-carboxylic acid: an orally active selective leukotriene B4 receptor antagonist | Q43714264 | ||
| Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis | Q43735870 | ||
| Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone | Q43820996 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 827096 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | PPAR Research | Q15756406 |
| P1476 | title | The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer | |
| P478 | volume | 2008 |
| Q41812157 | 5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis |
| Q64238408 | A combined computational strategy of sequence and structural analysis predicts the existence of a functional eicosanoid pathway in Drosophila melanogaster |
| Q47239487 | Arachidonic Acid Metabolite as a Novel Therapeutic Target in Breast Cancer Metastasis |
| Q90208734 | Bexarotene Exerts Protective Effects Through Modulation of the Cerebral Vascular Smooth Muscle Cell Phenotypic Transformation by Regulating PPARγ/FLAP/LTB4 After Subarachnoid Hemorrhage in Rats |
| Q33966203 | Eicosanoids and cancer |
| Q34067846 | Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase. |
| Q34168476 | Nuclear receptors and pathogenesis of pancreatic cancer. |
| Q35210023 | Peroxisome proliferator-activated receptors and cancer: challenges and opportunities |
| Q24564308 | Regulation of inflammation in cancer by eicosanoids |
| Q63314665 | Role of Lipoxygenases in Pathogenesis of Cancer |
Search more.